Intrathecal interleukin-2 for melanomatous meningitis?

Journal of Clinical Oncology

Volumn 32, Issue 33, 2014, Pages e111-e113

  Shonka, Nicole A ^a   Kessinger, Anne M ^a   Aizenberg, Michele R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; ARTICLE; BRAIN RADIATION; CANCER RADIOTHERAPY; CASE REPORT; FEMALE; HUMAN; MELANOMA; MELANOMATOUS MENINGITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SENTINEL LYMPH NODE BIOPSY; SYSTEMATIC REVIEW; YOUNG ADULT; COMPLICATION; INTRASPINAL DRUG ADMINISTRATION; MENINGITIS;

ADULT; FEMALE; HUMANS; INJECTIONS, SPINAL; INTERLEUKIN-2; MELANOMA; MENINGITIS;

EID: 84911402630     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.1100     Document Type: Article

References (9)

1. American Cancer Society: Cancer facts and figures 2010. Atlanta, GA, American Cancer Society, 2010. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-026238.pdf
2. Howlader N, Noone AM, Krapcho M, et al (eds): SEER cancer statistics review. Bethesda, MD, National Cancer Institute, 1997-2009
3. Amer MH, Al-Sarraf M, Baker LH, et al: Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 42:660-668, 1978
4. Harstad L, Hess KR, Groves MD: Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 10:1010-1018, 2008
5. Moser RP, Bruner JM, Grimm EA: Biological therapy of brain tumors. Cancer Bull 43:117-126, 1991
6. Samlowski WE, Park KJ, Galinsky RE, et al: Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: Sequential evaluation of intracranial pressure, cerebrospinal fluid cytology, and cytokine induction. J Immunother Emphasis Tumor Immunol 13:49-54, 1993
7. Papadopoulos NE, Moser RP, Grimm E, et al: Intrathecal use of recombinant interleukin-2 (rIL-2) in the treatment of leptomeningeal disease (LMD) from metastatic melanoma. Proc Am Soc Clin Oncol 14, 1995 (abstr 1307
8. Fathallah-Shaykh HM, Zimmerman C, Morgan H, et al: Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2: A case report. Cancer 77:1544-1550, 1996
9. Papadopoulos NE, Gerber DL, Eton O, et al: The role of intrathecal (IT) use of interleukin-2 (IL-2) in the treatment of leptomeningeal disease (LMD) in patients (pts) with melanoma. Proc Am Soc Clin Oncol 21, 2002 (abstr 1408)